This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): NSI-189
NS-189 is the first in a class of compounds that Neuralstem plans to develop into orally administered drugs. These appear to have the effect of recruiting the patient's own neural stem cells to repair or protect against damage to the Central Nervous System (CNS) from disease or injury.
NSI-189 stimulated neurogenesis of human hippocampus-derived neural stem cells in-vitro. In mice, NSI-189 both stimulated neurogenesis of the hippocampus and increased its overall volume. Therefore, NSI-189 may reverse the human hippocampal atrophy seen in major depression and schizophrenia.
Deal Structure: In June 2011, Neuralstem announced that it has signed an exclusive agency licensing agreement with Summit Pharmaceuticals International Corporation, of Tokyo, Japan (SPI), a wholly owned subsidiary of Sumitomo Corporation Group. Under the agreement, SPI will market development and licensing rights to NSI-189 in Japan.
Partners: Summit Pharmaceuticals International
Additional information available to subscribers only: